Regeneron Pharmaceutical (NASDAQ:REGN) fell 4.3% after a court rejected its request for a temporary injunction blocking sales ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

RBC Capital notes that it was announced that the Court of Appeals denied Regeneron’s (REGN) motion for an emergency injunction and the ...

Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...

Recent health news includes a court ruling allowing Amgen's Eylea biosimilar launch, Starboard criticizing Kenvue's skin ...

The most pressing challenges include the financial and emotional burdens associated with frequent, long-term treatments for ...

A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected ...

Two billion dollars in investments. 4,500 employees. Regeneron has grown into a major economic engine — and it's now ...